semaglutide & tirzepatide weight loss and Injectable Correlated with Greatest Among GLP-1 Medications EASO Recommends Semaglutide, Tirzepatide for

Levels of fasting venous plasma lactate above the upper limit of normal but less than 5 mmol/L in patients taking metformin do not necessarily indicate impending lactic acidosis and may be explainable by other mechanisms, such as poorly controlled diabetes or obesity, vigorous physical activity, or technical problems in sample handling [see Warnings and Precautions]

The appetite-suppressing and metabolic benefits of GLP-1 therapy depend on consistent weekly receptor activation

The S form, not so much

and for both diabetes and obesity in other countries

Both are Novo Nordisk programs, but they employ fundamentally different molecular strategies